Self‐Correcting Method for Highly Effective Office‐Based Helicobacter pylori Therapy Using Cumulative Test of Cure Data

Abstract

ABSTRACTBackground and AimHelicobacter pylori infections have become resistant to many previously highly effective antimicrobial regimens resulting in clarithromycin, metronidazole, or fluoroquinolone‐containing therapies becoming unsuccessful. Pretreatment susceptibility testing is only widely available in the United States but is still rarely done. Here, we propose a framework to monitor H. pylori eradication in small clinical settings by routinely assessing the effectiveness of therapy.MethodsBecause of the small sample size in individual practice's, we assume an acceptable cure rate of ≥80% (preferred cure rate ≥85%) in adherent patients, with a dichotomous outcome (cured vs. failed) and consecutive patient enrollment. To obtain results (feedback) in a timely manner, for individual practices, cure rates can be estimated after 10 patients. Large practices which acquire patients more rapidly can delay analysis until a total of 104 H. pylori‐infected patients, assuming a baseline cure rate of at least 85% with the preferred regimen.ResultsWe show how data from individual practices can be utilized to improve the effectiveness of H. pylori treatment decisions. The method consists of recording and accumulating the confirmation of cure data for successive small groups of patients. These data are then analyzed as binary outcomes (pass‐fail) and serve as the basis for studying and improving the effectiveness of H. pylori treatment decisions.ConclusionA simple actuarial method can serve outpatient clinics to ensure a reliable test‐to‐cure method and avoid futile Hp regimens.